Breaking Finance News

A statement released earlier today by JP Morgan Cazenove about Abcam PLC (LON:ABC) bumps the target price to 781.00GBX

Boasting a price of 0.00GBX, Abcam PLC (LON:ABC) traded 1.66% higher on the day. The last stock price is down 22.74% from the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Abcam PLC has recorded a 50-day average of 752.69GBX and 200-day moving average of 672.96GBX. 743,577 shares of the stock traded hands, up from ann avg. volume of 661,193

In an issued report on 9/13/2016 JP Morgan Cazenove upped the target price of Abcam PLC (LON:ABC) from 581GBX to 781GBX reporting a possible upsideof 0.00%.

Previously on 9/12/2016, Numis released a statement about Abcam PLC(LON:ABC) kept the target price at 850.00GBX. At the time, this indicated a possible upside of 0.06%.

Performance Graphic:


Abcam PLC has a PE of 45 with a 52 week low of 547.00GBX and a one-year high of 831.00GBX and has a market cap of 0.0 GBX.

About Abcam PLC (LON:ABC)

Abcam plc is engaged in producing and marketing protein research tools. The Company offers products, such as primary antibodies, including monoclonals, polyclonals, conjugated primary antibodies, tags and cell markers, loading controls, flow cytometry antibodies and others; secondary antibodies, such as Alexa Fluor conjugated secondaries, alkaline phosphatase (AP), horseradish peroxidase (HRP), Biotin and others; immunoassay kits and reagents, such as lateral flow and dipstick assays, antibody arrays and others; cell and tissue imaging tools, such as fluorescent cell imaging and immunohistochemistry (IHC); cellular and biochemical assays, such as cell signaling, and cell damage and oxidative stress, and others; proteins and peptides, such as enzymes, signaling proteins and others; proteomics tools, cellular fractionation and others; lysates, such as cytoplasmic, membrane and others; multiplex micro ribonucleic acid (miRNA) assays, and agonists, activators, and antagonists and inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *